There are few investments more worth making than one for your health. In our latest study, we analysed eight countries in central and eastern Europe and found that, by all measures, lower healthcare spending leads to poorer health outcomes. As populations age and the economy continues to recover, policymakers should view greater healthcare expenditures as a necessary investment in economic growth and health system resiliency. Closing the gap between central and eastern European countries and their western European counterparts must be a priority for national governments – for the health of their citizens and economies.
Investing in a healthier economy
There are few investments more worth making than one for your health. In our latest study, we analysed eight countries in central and eastern Europe and found that, by all measures, lower healthcare spending leads to poorer health outcomes. As populations age and the economy continues to recover, policymakers should view greater healthcare expenditures as a necessary investment in economic growth and health system resiliency. Closing the gap between central and eastern European countries and their western European counterparts must be a priority for national governments – for the health of their citizens and economies.
For more on the benefits of healthier investments, read our full report in partnership with Economist Impact.
Related items
:focal())
News
20 May 2026
Healthcare, competitiveness, innovation and simplification
Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation.
The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment.
The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.
:focal())
Position Paper
19 May 2026
Strengthening EU competitiveness through an adaptive MDR/IVDR framework
Position Paper
19 May 2026
A global approach to strengthening Europe’s biotechnology ecosystem
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.